Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of wnt/β-catenin signaling pathway

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Xu, Xiaoming ^a   Mao, Wei ^a   Chen, Qian ^b   Zhuang, Qin ^b   Wang, Lihui ^b   Dai, Jin ^a   Wang, Haibing ^a   Huang, Zhaoquan ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; RECOMBINANT ENDOSTATIN; VASCULOTROPIN; ENDOSTAR PROTEIN; ENDOSTATIN; RECOMBINANT PROTEIN; T CELL FACTOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; WNT PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BETA CATENIN SIGNALING PATHWAY; CAPILLARY ENDOTHELIAL CELL; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LUCIFERASE ASSAY; MIGRATION INHIBITION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

BETA CATENIN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; ENDOSTATINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS; WNT SIGNALING PATHWAY; WOUND HEALING;

EID: 84907209949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107463     Document Type: Article

References (44)

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
2. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V (2006) Neovascularization in human atherosclerosis. Circulation 113: 2245-2252.
3. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP (2009) Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 5: 8-13.
4. Cabebe E, Wakelee H (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8: 15-27.
5. Doyle B, Caplice N (2007) Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49: 2073-2080.
6. Simo R, Hernandez C (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51: 1574-1580.
7. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, et al. (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovasculariza-tion and plaque growth in apolipoprotein E-deficient mice. Circulation 99: 1726-1732.
8. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, et al. (2001) Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7: 3366-3374.
9. Jia H, Kling J (2006) China offers alternative gateway for experimental drugs. Nat Biotechnol 24: 117-118.
10. Hu W, Xia LJ, Chen FH, Wu FR, Tang J, et al. (2012) Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-alpha, IL-1beta production. Inflamm Res 61: 827-835.
11. Mao W, Kong J, Dai J, Huang ZQ, Wang DZ, et al. (2010) Evaluation of recombinant endostatin in the treatment of atherosclerotic plaques and neovascularization in rabbits. J Zhejiang Univ Sci B 11: 599-607.
12. Ling Y, Yang Y, Lu N, You QD, Wang S, et al. (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84.
13. Ling Y, Lu N, Gao Y, Chen Y, Wang S, et al. (2009) Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res 29: 411-417.
14. Zhang L, Ge W, Hu K, Zhang Y, Li C, et al. (2012) Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep 39: 89-95.
15. Dejana E (2010) The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 107: 943-952.
16. Zerlin M, Julius MA, Kitajewski J (2008) Wnt/Frizzled signaling in angiogenesis. Angiogenesis 11: 63-69.
17. Rao TP, Kuhl M (2010) An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 106: 1798-1806.
18. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
19. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
20. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J (2005) Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 8: 43-51.
21. Planutiene M, Planutis K, Holcombe RF (2011) Lymphoid enhancer-binding factor 1, a representative of vertebrate-specific Lef1/Tcf1 sub-family, is a Wnt-beta-catenin pathway target gene in human endothelial cells which regulates matrix metalloproteinase-2 expression and promotes endothelial cell invasion. Vasc Cell 3: 28.
22. Lai SL, Cheah SC, Wong PF, Noor SM, Mustafa MR (2012) In vitro and in vivo anti-angiogenic activities of Panduratin A. PLoS One 7: e38103.
23. Wang Q, Sun ZX, Allgayer H, Yang HS (2010) Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 29: 128-138.
24. Du Q, Park KS, Guo Z, He P, Nagashima M, et al. (2006) Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 66: 7024-7031.
25. Cowan CE, Kohler EE, Dugan TA, Mirza MK, Malik AB, et al. (2010) Kruppel-like factor-4 transcriptionally regulates VE-cadherin expression and endothelial barrier function. Circ Res 107: 959-966.
26. Patan S (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32.
27. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI (2007) Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 39: 212-220.
28. Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, et al. (2011) Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett 301: 212-220.
29. Yu D, Wu H, Yang B, Yang K, Liu H, et al. (2013) Antitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway. Acta Biochim Biophys Sin (Shanghai) 45: 742-748.
30. Jin F, Ji H, Jia C, Brockmeier U, Hermann DM, et al. (2012) Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116. PLoS One 7: e47161.
31. Goodwin AM, Sullivan KM, D'Amore PA (2006) Cultured endothelial cells display endogenous activation of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signaling. Dev Dyn 235: 3110-3120.
32. Corada M, Nyqvist D, Orsenigo F, Caprini A, Giampietro C, et al. (2010) The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell 18: 938-949.
33. Cattelino A, Liebner S, Gallini R, Zanetti A, Balconi G, et al. (2003) The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol 162: 1111-1122.
34. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, et al. (2010) Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci USA 107: 6900-6905.
35. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790.
36. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821.
37. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527.
38. Xu WJ, Huang C, Wang J, Jiang RC, Wang LC, et al. (2011) Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states. Chin Med J (Engl) 124: 2883-2889.
39. Li Z, Wang C, Jiao X, Lu Y, Fu M, et al. (2006) Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 26: 4240-4256.
40. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
41. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, et al. (2004) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 137: 668-674.
42. Zhang X, Gaspard JP, Chung DC (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050-6054.
43. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, et al. (2003) beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 63: 3145-3153.
44. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, et al. (2005) Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 96: 308-318.